Enhanced drug delivery by a prodrug approach effectively relieves neuroinflammation in mice.

[1]  Guo Ci Teo,et al.  dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts , 2022, Nature Communications.

[2]  K. Huttunen,et al.  Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands , 2021, Molecules.

[3]  M. Blanco,et al.  Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders. , 2021, RSC medicinal chemistry.

[4]  J. Masdeu,et al.  Neuroinflammation is highest in areas of disease progression in semantic dementia. , 2021, Brain : a journal of neurology.

[5]  K. Huttunen,et al.  Improved L-Type Amino Acid Transporter 1 (LAT1)-Mediated Delivery of Anti-Inflammatory Drugs into Astrocytes and Microglia with Reduced Prostaglandin Production. , 2021, International journal of pharmaceutics.

[6]  Z. Zdráhal,et al.  SP3 Protocol for Proteomic Plant Sample Preparation Prior LC-MS/MS , 2021, Frontiers in Plant Science.

[7]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[8]  Peter S. Jones,et al.  Neuroinflammation predicts disease progression in progressive supranuclear palsy , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  A. Emili,et al.  Loss of G-Protein Pathway Suppressor 2 Promotes Tumor Growth Through Activation of AKT Signaling , 2021, Frontiers in Cell and Developmental Biology.

[10]  S. Auriola,et al.  L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells. , 2020, ACS chemical neuroscience.

[11]  R. Zaragozá.  Transport of Amino Acids Across the Blood-Brain Barrier , 2020, Frontiers in Physiology.

[12]  K. Huttunen,et al.  Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival , 2020, Molecular Neurobiology.

[13]  I. Fyfe.  Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease , 2020, Nature Reviews Neurology.

[14]  M. Lekander,et al.  Comparison of bacterial lipopolysaccharide-induced sickness behavior in rodents and humans: Relevance for symptoms of anxiety and depression , 2020, Neuroscience & Biobehavioral Reviews.

[15]  H. Bramlett,et al.  IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis , 2020, Journal of Neuroinflammation.

[16]  J. Wiśniewski.  Filter Aided Sample Preparation - A tutorial. , 2019, Analytica chimica acta.

[17]  Christoph B. Messner,et al.  DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput , 2019, Nature Methods.

[18]  Li Hai,et al.  Ascorbic acid-modified brain-specific liposomes drug delivery system with "lock-in" function. , 2019, Chemistry and physics of lipids.

[19]  M. Hiltunen,et al.  l-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia , 2019, Scientific Reports.

[20]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[21]  N. Ip,et al.  Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities. , 2018, ACS chemical neuroscience.

[22]  T. Natunen,et al.  Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target , 2018, Basic & clinical pharmacology & toxicology.

[23]  J. Koistinaho,et al.  Alzheimer’s Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes , 2018, Pharmaceutical Research.

[24]  T. Nishimura,et al.  Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line , 2018, Pharmaceutical Research.

[25]  Jürgen Cox,et al.  A Network Module for the Perseus Software for Computational Proteomics Facilitates Proteome Interaction Graph Analysis , 2018, bioRxiv.

[26]  K. Brouwer,et al.  Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.

[27]  Muzamil Saleem,et al.  Low-dose NSAIDs reduce pain via macrophage targeted nanoemulsion delivery to neuroinflammation of the sciatic nerve in rat , 2018, Journal of Neuroimmunology.

[28]  K. Hansen,et al.  Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist. , 2017, Journal of medicinal chemistry.

[29]  K. Suk,et al.  Astrocytic Orosomucoid-2 Modulates Microglial Activation and Neuroinflammation , 2017, The Journal of Neuroscience.

[30]  George T Grossberg,et al.  Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics , 2017, Expert review of neurotherapeutics.

[31]  J. Schuetz,et al.  ABCB6, an ABC Transporter Impacting Drug Response and Disease , 2017, The AAPS Journal.

[32]  J. Leppänen,et al.  Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure , 2016, Neurochemical Research.

[33]  J. A. Spicer,et al.  A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells. , 2016, Journal of medicinal chemistry.

[34]  M. Sharman,et al.  Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease , 2016, Neurochemistry International.

[35]  Vikas Kumar,et al.  Low dose aspirin like analgesic and anti-inflammatory activities of mono-hydroxybenzoic acids in stressed rodents. , 2016, Life sciences.

[36]  P. Bergold.  Treatment of traumatic brain injury with anti-inflammatory drugs , 2016, Experimental Neurology.

[37]  S. G. Patching.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery , 2017, Molecular Neurobiology.

[38]  Matthias Mann,et al.  Parallel Accumulation-Serial Fragmentation (PASEF): Multiplying Sequencing Speed and Sensitivity by Synchronized Scans in a Trapped Ion Mobility Device. , 2015, Journal of proteome research.

[39]  David L Waning,et al.  Assessment of muscle mass and strength in mice. , 2015, BoneKEy reports.

[40]  N. Vale.  3.1 Amino Acids and Peptides in Medicine: Old or New Drugs? , 2015 .

[41]  Marco Y. Hein,et al.  Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ * , 2014, Molecular & Cellular Proteomics.

[42]  Vincenzo Pucci,et al.  Standardized workflows for increasing efficiency and productivity in discovery stage bioanalysis. , 2013, Bioanalysis.

[43]  K. Stejskal,et al.  Suppression of peptide sample losses in autosampler vials. , 2013, Journal of proteome research.

[44]  J. Leppänen,et al.  Erratum to: Design, Synthesis and Brain Uptake of LAT1-Targeted Amino Acid Prodrugs of Dopamine , 2013, Pharmaceutical Research.

[45]  Emma Lloyd Raven,et al.  The regulatory role of heme in neurons. , 2011, Metallomics : integrated biometal science.

[46]  J. Leppänen,et al.  Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. , 2011, Molecular pharmaceutics.

[47]  Takashi Suzuki,et al.  Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.

[48]  C. Kruse,et al.  Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. , 2010, Brain : a journal of neurology.

[49]  Y. Yeung,et al.  Rapid Detergent Removal from Peptide Samples with Ethyl Acetate for Mass Spectrometry Analysis , 2010, Current protocols in protein science.

[50]  M. Tansey,et al.  Molecular Neurodegeneration BioMed Central Review , 2009 .

[51]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[52]  C. Stichel,et al.  Upregulation of cathepsin S in the aging and pathological nervous system of mice , 2008, Brain Research.

[53]  C. DeCarli,et al.  Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham study , 2007, BMC Medical Genetics.

[54]  T. Terasaki,et al.  Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development , 2007, Pharmaceutical Research.

[55]  E. Ling,et al.  Microglial activation and its implications in the brain diseases. , 2007, Current medicinal chemistry.

[56]  Q. Smith.  Carrier-mediated transport to enhance drug delivery to brain , 2005 .

[57]  T. Järvinen,et al.  Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[58]  J. Couzin.  Halt of Celebrex Study Threatens Drug's Future, Other Trials , 2004, Science.

[59]  D. Selkoe,et al.  The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. , 1995, The American journal of pathology.